Evaluating only Athenex FDA Rejection’s profile at its peak — without knowing the outcome — the model ranked Founder chaos as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
FUNDING
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Athenex developed an oral formulation of paclitaxel, a chemotherapy drug typically administered intravenously. The convenience advantage was clear — patients could take cancer treatment at home rather than visiting infusion centers. The company raised $450M and reached a $2.5B market cap on the NYSE. In February 2021, the FDA issued a Complete Response Letter rejecting the drug due to concerns about trial design and efficacy endpoints. The stock fell 60% in a single day. The company pivoted to other pipeline assets but the lost years and capital were unrecoverable. By 2022 the share price was down 95% from peak.
Lesson
“Oral bioavailability reformulations have a high FDA scrutiny bar on non-inferiority — assume CRL risk when building the business model.”